Use of the epidermal growth factor receptor inhibitors gefitinib, erlotinib, afatinib, dacomitinib, and icotinib in the treatment of non-small-cell lung cancer: a systematic …
PM Ellis, N Coakley, R Feld, S Kuruvilla, YC Ung - Current oncology, 2015 - mdpi.com
Introduction: This systematic review addresses the use of epidermal growth factor receptor
(egfr) inhibitors in three populations of advanced non-small-cell lung cancer (nsclc) patients …
(egfr) inhibitors in three populations of advanced non-small-cell lung cancer (nsclc) patients …
[HTML][HTML] Targeted therapy for older patients with non-small cell lung cancer: Systematic review and guidelines from the French Society of Geriatric Oncology (SoFOG) …
L Greillier, M Gauvrit, E Paillaud, N Girard, C Montégut… - Cancers, 2022 - mdpi.com
Simple Summary Targeted therapy has become essential in the treatment of non-small cell
lung cancer (NSCLC). There are currently no guidelines for older patients who are frailer …
lung cancer (NSCLC). There are currently no guidelines for older patients who are frailer …
Phase III, randomized, double-blind, placebo-controlled trial of gemcitabine/cisplatin alone or with sorafenib for the first-line treatment of advanced, nonsquamous non …
LG Paz-Ares, B Biesma, D Heigener… - Journal of Clinical …, 2012 - ascopubs.org
Purpose This trial evaluated the efficacy and safety of sorafenib plus gemcitabine/cisplatin in
chemotherapy-naive patients with unresectable stage IIIB to IV nonsquamous non–small …
chemotherapy-naive patients with unresectable stage IIIB to IV nonsquamous non–small …
EGFR activation is a potential determinant of primary resistance of hepatocellular carcinoma cells to sorafenib
Z Ezzoukhry, C Louandre, E Trécherel… - … journal of cancer, 2012 - Wiley Online Library
Sorafenib is currently the medical treatment of reference for hepatocellular carcinoma
(HCC), but it is not known whether sorafenib is equally active in all HCC. Here, our aim was …
(HCC), but it is not known whether sorafenib is equally active in all HCC. Here, our aim was …
Primary and acquired resistance of colorectal cancer to anti-EGFR monoclonal antibody can be overcome by combined treatment of regorafenib with cetuximab
S Napolitano, G Martini, B Rinaldi, E Martinelli… - Clinical Cancer …, 2015 - AACR
Purpose: In colorectal cancer, the activation of the intracellular RAS–RAF and PIK3CA–AKT
pathways has been implicated in the resistance to anti-EGFR mAbs. We have investigated …
pathways has been implicated in the resistance to anti-EGFR mAbs. We have investigated …
A Phase II Study of Sorafenib in Patients with Platinum-Pretreated, Advanced (Stage IIIb or IV) Non–Small Cell Lung Cancer with a KRAS Mutation
AMC Dingemans, WW Mellema, HJM Groen… - Clinical Cancer …, 2013 - AACR
Abstract Purpose: Sorafenib inhibits the Ras/Raf pathway, which is overactive in cancer
patients with a KRAS mutation. We hypothesized that patients with non–small cell lung …
patients with a KRAS mutation. We hypothesized that patients with non–small cell lung …
Signaling intermediates (MAPK and PI3K) as therapeutic targets in NSCLC
L Ciuffreda, U Cesta Incani… - Current …, 2014 - ingentaconnect.com
The RAS/RAF/MEK/ERK and the PI3K/AKT/mTOR pathways govern fundamental
physiological processes, such as cell proliferation, differentiation, metabolism, cytoskeleton …
physiological processes, such as cell proliferation, differentiation, metabolism, cytoskeleton …
Safety and feasibility of targeted agent combinations in solid tumours
SR Park, M Davis, JH Doroshow… - Nature reviews Clinical …, 2013 - nature.com
The plethora of novel molecular-targeted agents (MTAs) has provided an opportunity to
selectively target pathways involved in carcinogenesis and tumour progression …
selectively target pathways involved in carcinogenesis and tumour progression …
Escin enhanced the efficacy of sorafenib by autophagy‐mediated apoptosis in lung cancer cells
Combining anti‐cancer drugs has been exploited as promising treatment strategy to target
lung cancer. Synergistic chemotherapies increase anti‐cancer effect and reduce effective …
lung cancer. Synergistic chemotherapies increase anti‐cancer effect and reduce effective …
Non-small-cell lung cancer: molecular targeted therapy and personalized medicine–drug resistance, mechanisms, and strategies
M Sechler, AD Cizmic, S Avasarala… - Pharmacogenomics …, 2013 - Taylor & Francis
Targeted therapies for cancer bring the hope of specific treatment, providing high efficacy
and in some cases lower toxicity than conventional treatment. Although targeted …
and in some cases lower toxicity than conventional treatment. Although targeted …